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journal homepage: www.elsevier .com/locate/ IPEJNew technologies for catheter based treatment of
paroxysmal atrial fibrillation e Everything under
control?We have been privileged in the past decades to witness the
logic of scientific discovery bringing to light the mechanistic
understanding and modern treatment of atrial fibrillation
(AF). From being experimental in their early days, catheter-
based techniques are now recommended as a Class 1 ther-
apy for treatment of patients with symptomatic AF refractory
to at least one membrane active antiarrhythmic medication
[1]. However, while catheter ablation using radiofrequency
(RF) energy is very efficient in suppression or even cure of
many supraventricular and ventricular arrhythmias, it is far
from reaching similar outcomes in more complex arrhyth-
mias such as AF, as reflected in reported “re-do” AF ablation
procedure rates of up to 50% [2,3]. Certainly, such frustrating
numbers may raise the question whether we are doing the
right thing, using the right tools and last but not least, un-
derstand what we are actually doing by using them. It is well
known that reconnection of at least one pulmonary vein (PV)
is present in nearly 100% of patients undergoing a “re-do”
procedure due to arrhythmia recurrence, and therefore the
creation of durable lesions is crucial for a permanent PV
isolation (PVI) and freedomof arrhythmic events [4,5]. There is
no doubt that successful arrhythmia treatment by RF ablation
depends on a critical understanding of the biophysics of lesion
creation and its control by e.g. titrating conventional param-
eters such as power, time and irrigation rate [6]. However,
significant variability in lesion size may be responsible for
both inefficacy as well as complications. Contact between
electrode and tissue and, thus, catheter contact force (CF) has
been shown to be a key parameter to control lesion size [7].
In this issue of the Indian Pacing and Electrophysiology
Journal, Fichtner et al. (REF) report their results on a series of
patients who underwent ipsilateral circumferential PVI for
drug refractory paroxysmal AF either CF aided using the
SmartTouch (N ¼ 30, ST group) or without CF monitoring but
using the SurroundFlow catheter (N¼ 29, SF group) instead of
the standard design irrigated catheter. The rationale behind
the SF catheter is mainly a qualitatively improved widely
distributed over the entire tip electrode surface catheter tip
irrigation by compensating for changes in irrigation flowPeer review under responsibility of Indian Heart Rhythm Society.with a changing electrodeetissue contact orientation, as well
as a decrease in required irrigation flow rate and delivery of
high RF power even in areas of very low blood flow and
potentially reduction in the risk of thrombus coagulum for-
mation [4]. These characteristics render the SF catheter a
powerful tool, but can result in marked temperature dispar-
ities between the catheter tip and the tissue during RF de-
livery. Of note, tissue temperatures of more than 100 C can
be reached, without the ability to control lesion formation.
Initial enthusiasm has been put into perspective after a
recently published prospective observational study on steam
pop formation with different power and irrigation rate set-
tings suggesting that merely creating efficient lesions may
not be the optimal approach when an adequate control and
feedback are lacking [8].
In the present study, patients were consecutively included
between 2011 and 2012 e a significant detail in view of
important lessons we have learned since then. Baseline
characteristics were well balanced between the two groups;
procedural data comparable without any significant differ-
ences and maximal power settings during PVI identical
(25e30W, irrigation rate 30 ml/min in the ST group and 17ml/
min in the SF group). Of note, a CF of 10e20 g was targeted in
the ST group during PVI but no data on actual achieved CFs
was provided. Complete PVI was validated by an unexcitable
ablation line to pacing (10 V, 2 ms) and entry and exit block,
although no Adenosine was used. And all patients were dis-
charged on betablockers without any other antiarrhythmic
drugs and followed for 6 months using an intensive follow-up
regimen, with a strict definition of success: freedom from
documented symptomatic or asymptomatic AF or atrial
tachycardia after a blanking period of 6 weeks and off drugs
after a single procedure.
The authors are to be congratulated for their robust anal-
ysis. It allows unequivocal interpretation of gathered results,
summarized as a 72% freedom from atrial arrhythmias within
6 months in both groups with low and comparable adverse
events, driving the authors to the conclusion that CF guided
PVI reaches the same success rate as PVI without CF moni-
toring using a SF catheter. One may argue that pre-specified
complication rates based on the current literature could not
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comparison in terms of safety difficult, however, neither was
this the primary aim of the authors, nor could any differences
be expected in this regard between the two groups.
Do these outcomes unequivocally indicate that the use of
real-time CF monitoring catheters has not been able to
improve the efficacy and sustainability of lesion formation
and clinical success rates? The possible answer is that out-
comes depend on how we use these tools and what they are
compared with. Of note, success rates when using novel tools
certainly also depend on experience and proficiency of the
operator. The recently published SMART-AF trial showed a
success rate of 72.5%, perfectly in line with the study by
Fichtner et al., however, at 12 months [9], whereas earlier
studies using a traditional Navistar Thermocool catheter
reached a 66% success rate and perhaps these success rates
allow us to acknowledge the improved outcomes of Fichtner
et al. with the SF [10]. The better outcomes in SMART-AF on
the other hand may be explained by the use of CF monitoring,
by a better understanding of efficient lesion formation and its
control for a sustained PV isolation and also by effective
strategies to improve contact: deflectable sheaths, intracar-
diac echocardiography, measurement of catheter tip imped-
ance dynamics, general anesthesia. These issues remain
unmentioned in the study by Fichtner et al. as does the
probably most important information when performing CF
guided PVI: the percentage of RF time reaching target CF and
FTI values. In the SMART-AF trial, the investigators indeed
found that an increased percentage of time within physician-
chosen target CF ranges correlated with increased freedom
from arrhythmia recurrence, with 84.4% of subjects being
arrhythmia-free at 12 months when CF was within the tar-
geted range >82% of the time [9]. The EFFICAS II trial, pub-
lished this year, prospectively evaluated a set of CF guidelines
for ensuring durable isolation of the PVs (target CF of 20 g,
range of 10e30 g, minimum FTI of 400 gs) using the TactiCath
catheter. Not surprisingly, their use and continuity in
deployment of RF lesions along the ablation line resulted in a
superior rate of durable PVI [11]. Similarly, the TOCCASTAR
study, investigating the primary effectiveness end point con-
sisting of acute electrical isolation of all PVs and freedom from
recurrent symptomatic atrial arrhythmia off all antiar-
rhythmic drugs at 12 months, clearly showed an improved
effectiveness and outcome when optimal CF values (10 g)
were achieved [12].
In conclusion, the analysis by Fichtner et al. adds to the
evidence that catheters with real-time CF sensing have
become essential for safe and efficient catheter-based treat-
ment of AF and may define new standards of care in order to
improve efficacy and guarantee permanent PVI while keeping
complication rates low [13]. Significant challenges remain,
including how to decrease the incidence of left atrial flutters
by avoiding lines and preventing gaps, how to avoid excessive
redundant atrial ablation and how to translate these tasks
into the patients' freedom of arrhythmic events. Surely,
sooner or later more efficient and powerful tools will find their
way into our clinical routine, however, after having appreci-
ated the “history of lesion formation” so far one statementwill
probably hold true even more: “power is nothing without
control”.r e f e r e n c e s
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